Similar to our work, mice harboring NTRK1 and TP53 comutations developed a highly aggressive erythroid leukemia that was very responsive to larotrectinib, further highlighting the relevance of Trk inhibitors for clinical trials in patients with hematological malignancies [79]. The gene discussed is NTRK1; the disease is hematologic disorder.